Description: <p>β-Caryophyllene is a dietary sesquiterpene and CB2 agonist with preclinical anticancer evidence, including apoptosis induction, reduced proliferation, anti-angiogenesis, reduced invasion/migration, and chemo/radio-sensitization. Evidence is promising but remains mainly in-vitro and animal-based; clinical cancer validation is lacking.<br>
-naturally occurring sesquiterpene found in many plant essential oils: black pepper, clove oil ...<br>
-binds selectively to the CB2 receptors(modulates up) and not the CB1 receptor, which makes it non-psychoactive and therapeutically appealing.
</p>
-Ylang-Ylang leaves have been found to contain the highest concentration of BCP (52%)<br>
-black pepper, 30% BCP in its fruit-derived essential oil.<br>
-leaves of the tropical tree Spondias pinnata yield 49.9% BCP <br>
-Pimpinella kotschyana, a Mediterranean herb, was found to contain 49.9% BCP in its seeds <br>
-Sumac fruits contain 34.3% BCP<br>
-clove buds contain 20–30% BCP in their essential oil<br>
-certain cannabis strains, flowers can produce BCP concentrations of approximately 30%<br>
-sugar apples leaves contain 22.9% BCP<br>
<p><b>Beta-Caryophyllene</b> — β-Caryophyllene is a plant-derived bicyclic sesquiterpene hydrocarbon and dietary cannabinoid with selective functional agonism at cannabinoid receptor type 2. It is formally classified as a natural sesquiterpene terpene, food flavoring compound, and investigational phytochemical adjunct rather than an approved anticancer drug. Standard abbreviations include BCP, β-CP, and sometimes trans-caryophyllene. It occurs in multiple essential oils, especially black pepper, clove, copaiba, oregano, hops, rosemary, and Cannabis sativa chemotypes, but its database identity should be the purified compound rather than a whole-oil product.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>CB2-centered anti-inflammatory and immunomodulatory signaling, with low CB1 activity and therefore no intrinsic THC-like psychoactive classification.</li>
<li>Suppression of pro-survival oncogenic signaling, especially PI3K/Akt/mTOR, STAT3, NF-κB, and related proliferation or survival pathways in cancer models.</li>
<li>Induction of mitochondrial apoptosis through Bax/Bcl-2 shift, caspase activation, mitochondrial stress, and cell-cycle arrest in several cancer cell lines.</li>
<li>Anti-angiogenic and anti-migratory activity, including inhibition of endothelial migration, tube formation, VEGF-linked responses, EMT, invasion, and metastasis-associated phenotypes.</li>
<li>Chemosensitization, mainly preclinical, reported with cisplatin and other cytotoxic or targeted agents; mechanism appears context-dependent and partly linked to apoptosis and resistance-pathway modulation.</li>
<li>Radiosensitization, currently preliminary and model-dependent, with recent colorectal cancer cell evidence involving PPARγ-mediated apoptosis.</li>
<li>ROS/NRF2 modulation is secondary and context-dependent: BCP can promote oxidative stress in cancer-cell apoptosis models, while in normal injury models it more often shows cytoprotective antioxidant and NRF2-linked effects.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> BCP is highly lipophilic and formulation-sensitive; oral exposure is limited and variable with conventional dosing, while self-emulsifying lipid formulations can substantially improve human systemic exposure. PK relevance is high because many in-vitro anticancer concentrations are unlikely to be reproduced by normal dietary intake.</p>
<p><b>Delivery constraints:</b> The key delivery constraints are volatility, hydrophobicity, oxidation/stability, low aqueous solubility, food-matrix dependence, and the likely need for lipid, nanoemulsion, SEDDS, or other formulation strategies if systemic pharmacology is the goal.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer assays use micromolar-to-high-micromolar or µg/mL concentrations; these should be interpreted cautiously because common in-vitro levels likely exceed exposures achievable from culinary intake. Formulated oral BCP may improve exposure, but clinical anticancer target engagement has not been established.</p>
<p><b>Clinical evidence status:</b> Preclinical oncology evidence is moderate and spans cell, endothelial, and animal models; human evidence is small and mostly non-oncology or PK-focused. No validated clinical cancer efficacy evidence was found. Best database status is preclinical / investigational adjunct, with possible chemosensitizer and anti-angiogenic tags marked as preclinical.</p>
<h3>Beta-Caryophyllene Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CB2 receptor signaling</td>
<td>CB2 engagement may shift inflammatory and survival signaling ↓ (context-dependent)</td>
<td>CB2-mediated inflammation ↓ with low CB1 psychoactivity</td>
<td>R/G</td>
<td>Anti-inflammatory and immunomodulatory signaling</td>
<td>Core pharmacologic identity of BCP; direct anticancer dependence on CB2 varies by model.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K Akt mTOR STAT3 survival signaling</td>
<td>PI3K/Akt/mTOR ↓; STAT3 ↓; proliferation ↓; survival ↓</td>
<td>Usually cytoprotective or neutral at lower exposure (context-dependent)</td>
<td>R/G</td>
<td>Growth suppression and apoptosis sensitization</td>
<td>Central anticancer axis across bladder, ovarian, lung, and other cell models; not yet clinically validated.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial apoptosis</td>
<td>Bax ↑; Bcl-2 ↓; caspase-3 ↑; mitochondrial stress ↑; apoptosis ↑</td>
<td>In injury models, mitochondrial dysfunction often ↓</td>
<td>G</td>
<td>Intrinsic apoptotic cell death</td>
<td>Strong recurring preclinical mechanism; cancer selectivity depends on dose and model.</td>
</tr>
<tr>
<td>4</td>
<td>Angiogenesis and endothelial migration</td>
<td>VEGF-linked angiogenesis ↓; invasion ↓; migration ↓</td>
<td>Endothelial migration and tube formation ↓ (model-dependent)</td>
<td>G</td>
<td>Anti-angiogenic and anti-metastatic pressure</td>
<td>Important for colorectal xenograft and endothelial assay interpretation; may be therapeutically relevant but exposure-limited.</td>
</tr>
<tr>
<td>5</td>
<td>NF-κB inflammatory signaling</td>
<td>NF-κB-linked survival and cytokine tone ↓ (context-dependent)</td>
<td>Inflammatory cytokine signaling ↓</td>
<td>R/G</td>
<td>Inflammation-linked tumor support reduction</td>
<td>More robust as an anti-inflammatory mechanism than as a standalone cancer-killing mechanism.</td>
</tr>
<tr>
<td>6</td>
<td>ROS and mitochondrial oxidative stress</td>
<td>ROS ↑ can contribute to apoptosis (high concentration only)</td>
<td>Oxidative stress ↓ in many toxic injury models</td>
<td>R/G</td>
<td>Context-dependent redox modulation</td>
<td>antioxidant or pro-oxidant; direction depends on cell type, injury context, and concentration.</td>
</tr>
<tr>
<td>7</td>
<td>NRF2 cytoprotection</td>
<td>↔ or context-dependent; may be undesirable if it protects malignant cells</td>
<td>NRF2/HO-1/NQO1 ↑ in injury-protection models</td>
<td>G</td>
<td>Secondary antioxidant-response modulation</td>
<td>NRF2 is not a core anticancer mechanism for BCP; tag as secondary/contextual rather than primary.</td>
</tr>
<tr>
<td>8</td>
<td>Chemosensitization</td>
<td>Cisplatin response ↑; apoptosis ↑; resistance signaling ↓ (model-dependent)</td>
<td>Normal-cell toxicity data are insufficient for oncology combinations</td>
<td>G</td>
<td>Adjunct sensitization</td>
<td>Preclinical evidence supports a sensitizer hypothesis, but there is no clinical cancer validation.</td>
</tr>
<tr>
<td>9</td>
<td>Radiosensitization</td>
<td>Radiation response ↑ in colorectal cancer cells (model-dependent)</td>
<td>Normal-tissue radioprotection versus radiosensitization is unresolved</td>
<td>G</td>
<td>Potential radiation adjunct</td>
<td>Recent evidence is early and should be tagged as preliminary, not established.</td>
</tr>
<tr>
<td>10</td>
<td>Glycolysis and HIF-1α</td>
<td>↔ limited direct oncology evidence</td>
<td>↔ not a primary established axis</td>
<td>G</td>
<td>Not a core mechanism</td>
<td>Do not add strong HIF-1α or glycolysis tags unless future product-specific cancer evidence supports them.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Effective in-vitro exposure may exceed practical dietary exposure</td>
<td>Food-use safety does not establish therapeutic-dose safety</td>
<td>G</td>
<td>PK and evidence limitation</td>
<td>Key constraints are bioavailability, formulation, dose, tissue exposure, cancer-type heterogeneity, and lack of oncology trials.</td>
</tr>
</tbody>
</table>
<p><b>TSF legend:</b> P: 0–30 min; R: 30 min–3 hr; G: >3 hr</p>